drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy
drug_description
Autologous double-negative (CD4−/CD8−) T cells transduced via lentiviral vector to express an anti-CD19 chimeric antigen receptor; depletes CD19+ B-lineage cells and plasmablasts to reduce autoantibody production and B cell–mediated inflammation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous double-negative (CD4-/CD8-) T cells are lentivirally engineered to express an anti-CD19 chimeric antigen receptor; CAR engagement of CD19 triggers targeted cytotoxicity against CD19+ B-lineage cells and plasmablasts, reducing autoantibody production and B cell–mediated inflammation.
drug_name
CD19-CAR-DNT cells (RJMty19)
nct_id_drug_ref
NCT06316076